About this study
Differentiated thyroid cancer (DTC) is a type of thyroid cancer. Scientists have developed new drugs to target the genetic mutations (changes in a person’s DNA) that drive this cancer. These type of drugs are called targeted therapy and can shrink tumors in many cases. Research in adults has shown that these drugs can increase the tumor’s absorption of radioactive iodine. Radioactive iodine is a common treatment for thyroid cancer.
Patients in the TRAIT clinical trial have DTC that has spread to the lungs. These patients will receive targeted therapy for their cancer. They will also follow a low-iodine diet for 7–14 days and will have 2 whole-body scans to check how much radioactive iodine their cancer absorbs. The first scan will happen before they start targeted therapy, and the second will take place about 4 weeks later.
Researchers will compare the scans to see if there is a difference. Doctors will continue to check each patient’s medical records for up to 5 years to gather more information.
This study will help us learn if targeted therapy affects the way radioactive iodine is taken up by the cancer. What we learn could help us make better treatment plans in the future.
Eligibility overview
- Differentiated thyroid cancer
- Infants to adults
- Presence of an NTRK fusion, RET fusion, ALK fusion, BRAF V600 mutation, or other targetable alteration
- Metastatic disease in the lungs